One retrospective series demonstrated that brain RT and PD-1/PD-L1 blockade was relatively well-tolerated in patients with NSCLC brain metastases as toxicity rates were consistent with those seen with checkpoint inhibitors alone [128]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.